COMPASS Pathways announces further positive results from groundbreaking phase IIb trial of investigational COMP360… Dec 1, 2021
With 3 Granted Patents and 41 Pending, Small Pharma Is On Track To Be One Of Europe’s Biggest Psychedelic Companies Nov 19, 2021
COMPASS Pathways announces positive topline results from groundbreaking phase IIb trial of investigational COMP360… Nov 9, 2021
Small Pharma CEO On Innovative Passport Designation, Patents & More As Psychedelic Stock Surges Nov 1, 2021
European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive… Oct 25, 2021
Small Pharma Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy Sep 21, 2021